RxDoctor Payments Data

Edward Chock, MD

General Surgery · Oakdale, CANPI 1154423994

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by TELA Bio, Inc. at 29.7% of the total.

$179in general payments, 2019–2025

Across 9 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • TELA Bio, Inc.$53
  • Biohaven Pharmaceuticals, Inc.$44
  • Acell, Inc.$23
  • Biohaven Pharmaceutical Holding Company Ltd.$18
  • Lilly USA, LLC$15
  • Olympus America Inc.$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$179 in reported general payments places this provider in the 70th percentile of 167 general surgery providers in California.

See all general surgery providers in California

Medicare billing

Part B allowed, 2024
$100,803
Medicare patients
238
Services billed
1,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban92$54,451
EliquisApixaban72$54,267
RybelsusSemaglutide20$28,442
JanumetSitagliptin Phos/Metformin Hcl25$21,525
OzempicSemaglutide20$18,282
MyrbetriqMirabegron25$15,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,687
JanuviaSitagliptin Phosphate21$13,497
Breo ElliptaFluticasone/Vilanterol33$13,434
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen352$11,056
Spiriva HandihalerTiotropium Bromide13$6,898
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,163
BelsomraSuvorexant14$5,976
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,803
Tamsulosin Hcl213$4,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Belsomra$12$40,99760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 167 general surgery providers in California.

Other general surgery in Oakdale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →